Synergy Pharmaceuticals (SGYP) Touches $2.03 Low on Nov, 14; Profile of 10 Analysts Covering National-Oilwell Varco, Inc. (NOV)

November 14, 2017 - By Nellie Frank

Among 34 analysts covering National Oilwell Varco (NYSE:NOV), 10 have Buy rating, 6 Sell and 18 Hold. Therefore 29% are positive. National Oilwell Varco had 103 analyst reports since July 31, 2015 according to SRatingsIntel. As per Friday, June 2, the company rating was maintained by RBC Capital Markets. The company was downgraded on Tuesday, August 8 by SunTrust. The stock has “Outperform” rating by FBR Capital on Thursday, July 30. The firm earned “Hold” rating on Thursday, July 20 by RBC Capital Markets. The stock of National-Oilwell Varco, Inc. (NYSE:NOV) earned “Sector Perform” rating by Howard Weil on Thursday, February 4. Seaport Global downgraded the stock to “Sell” rating in Thursday, December 1 report. The company was maintained on Thursday, March 23 by Scotia Capital. The firm has “Accumulate” rating given on Friday, July 29 by Johnson Rice. As per Friday, March 3, the company rating was upgraded by Argus Research. Piper Jaffray maintained the stock with “Buy” rating in Thursday, October 26 report. See National-Oilwell Varco, Inc. (NYSE:NOV) latest ratings:

31/10/2017 Broker: Citigroup Rating: Neutral Old Target: $36 New Target: $35 Maintain
30/10/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $38 New Target: $36 Maintain
30/10/2017 Broker: JP Morgan Rating: Neutral Old Target: $30 New Target: $27 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $35.0 Maintain
26/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $36.0 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Sell New Target: $28.0 Maintain
10/10/2017 Broker: Deutsche Bank Rating: Hold New Target: $39 Initiates Coverage On
06/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $37.0 Maintain
06/10/2017 Broker: Cowen & Co Rating: Hold New Target: $30.0 Maintain
05/10/2017 Broker: Jefferies Rating: Hold New Target: $34.0 Maintain

The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reached all time low today, Nov, 14 and still has $1.91 target or 6.00% below today’s $2.03 share price. This indicates more downside for the $456.66M company. This technical setup was reported by Barchart.com. If the $1.91 PT is reached, the company will be worth $27.40M less. The stock decreased 16.80% or $0.41 during the last trading session, reaching $2.03. About 27.31 million shares traded or 312.54% up from the average. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since November 14, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.

Investors sentiment decreased to 0.67 in 2017 Q2. Its down 0.30, from 0.97 in 2017Q1. It turned negative, as 82 investors sold National-Oilwell Varco, Inc. shares while 216 reduced holdings. 50 funds opened positions while 151 raised stakes. 340.10 million shares or 1.18% less from 344.17 million shares in 2017Q1 were reported. Lombard Odier Asset Mgmt (Switzerland) reported 6,290 shares. Us Bank & Trust De holds 0.01% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV) for 110,472 shares. Guardian Life Insur Com Of America invested in 859 shares or 0% of the stock. 1,558 are owned by First Interstate Bancorp. Blb&B Advsr invested in 0.05% or 6,849 shares. Invesco stated it has 0.01% in National-Oilwell Varco, Inc. (NYSE:NOV). Kentucky Retirement Insurance Fund invested 0.06% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). High Pointe Ltd Liability Corp stated it has 0.68% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Wealthtrust reported 198 shares. Northpointe Capital Limited Co holds 0.21% or 60,008 shares in its portfolio. Parnassus Investments Ca stated it has 6.29M shares. Louisiana State Employees Retirement System reported 0.04% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Bartlett And Ltd reported 0% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Victory Mgmt owns 74,508 shares. Rand Wealth Ltd has invested 0.21% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV).

About 2.92M shares traded. National-Oilwell Varco, Inc. (NYSE:NOV) has risen 11.97% since November 14, 2016 and is uptrending. It has underperformed by 4.73% the S&P500.

National Oilwell Varco, Inc. is an oilfield equipment maker and technology provider. The company has market cap of $12.26 billion. The Firm operates through four divisions: Rig Systems, Rig Aftermarket, Wellbore Technologies and Completion & Production Solutions. It currently has negative earnings. The Rig Systems segment makes and supports the capital equipment and integrated systems needed to drill gas and oil wells on land and offshore.

Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $456.66 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Since May 26, 2017, it had 2 insider buys, and 0 insider sales for $43,302 activity. 6,500 Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares with value of $23,335 were bought by BRANCACCIO JOHN P. $19,967 worth of stock was bought by JACOB GARY S on Friday, May 26.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Synergy Pharmaceuticals had 31 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, October 29, the company rating was reinitiated by TH Capital. Cantor Fitzgerald initiated the stock with “Buy” rating in Thursday, June 1 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, October 18. BTIG Research maintained the shares of SGYP in report on Tuesday, August 1 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, November 9. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Outperform” rating given on Thursday, January 5 by Oppenheimer. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by Oppenheimer on Tuesday, October 10. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Buy” rating given on Monday, May 9 by Rodman & Renshaw. The firm has “Sell” rating by Citigroup given on Thursday, April 6. The rating was maintained by Rodman & Renshaw on Friday, January 20 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com